Chan Patrick Py, Wasinger Valerie C, Leong Rupert W
Patrick PY Chan, Valerie C Wasinger, Bioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, the University of NSW Australia, Kensington, NSW 2052, Australia.
World J Gastrointest Pathophysiol. 2016 Feb 15;7(1):27-37. doi: 10.4291/wjgp.v7.i1.27.
Recently, the field of proteomics has rapidly expanded in its application towards clinical research with objectives ranging from elucidating disease pathogenesis to discovering clinical biomarkers. As proteins govern and/or reflect underlying cellular processes, the study of proteomics provides an attractive avenue for research as it allows for the rapid identification of protein profiles in a biological sample. Inflammatory bowel disease (IBD) encompasses several heterogeneous and chronic conditions of the gastrointestinal tract. Proteomic technology provides a powerful means of addressing major challenges in IBD today, especially for identifying biomarkers to improve its diagnosis and management. This review will examine the current state of IBD proteomics research and its use in biomarker research. Furthermore, we also discuss the challenges of translating proteomic research into clinically relevant tools. The potential application of this growing field is enormous and is likely to provide significant insights towards improving our future understanding and management of IBD.
近年来，蛋白质组学领域在临床研究中的应用迅速扩展，其目标涵盖从阐明疾病发病机制到发现临床生物标志物等多个方面。由于蛋白质控制和/或反映潜在的细胞过程，蛋白质组学研究提供了一条有吸引力的研究途径，因为它能够快速识别生物样品中的蛋白质谱。炎症性肠病（IBD）包括几种胃肠道的异质性慢性疾病。蛋白质组学技术为应对当今IBD的主要挑战提供了有力手段，特别是在识别生物标志物以改善其诊断和管理方面。本综述将探讨IBD蛋白质组学研究的现状及其在生物标志物研究中的应用。此外，我们还将讨论将蛋白质组学研究转化为临床相关工具所面临的挑战。这个不断发展的领域的潜在应用是巨大的，很可能为增进我们未来对IBD的理解和管理提供重要的见解。
